Fuiano G, Di Filippo S, Memoli B, Cioffi M, Caglioti A, Mazza G
G Ital Nefrol. 2004 May-Jun;21 Suppl 28:S1-10.
Acute renal failure (ARF) in patients admitted to the intensive care unit (ICU) is mostly caused by ischemic or toxic injury, with a higher incidence in the latest years due to the growing number of interventions in cardiac and vascular surgery and to the general enhancement of reanimation techniques, which allow a better outcome among ICU patients. In critically ill patients, the ARF incidence reported in the literature ranges between 1 and 25%. Among ICU patients with ARF the mortality is between 40 and 65%, much more than in patients without this complication. Higher mortality rates, longer hospitalisation times and higher therapy costs demand from us an early diagnosis and treatment of ARF. Due to the lack of controlled and randomized proofs, recommended criteria for starting renal replacement therapy (RRT) in critical ARF patients might overlap with those for ESRD therapy. Moreover, randomised and controlled trials, confirming the actual efficacy of early onset of RRT on the mortality rate, are not yet available. As for stable ESRD patients, a direct relationship between dialytic doses and mortality and morbidity has been established for ARF patients. For ARF patients, as well as for ESRD patients, a minimum Kt/V of 1.2 three times a week should be ensured, although higher doses for critical ARF patients may achieve better results. The choice between intermittent (IRRT) and continuous renal replacement therapy (CRRT) in these patients is still a controversial issue. In spite of the fact that most studies report a better outcome in patients treated with CRRT, a recent meta-analysis failed to demonstrate any difference on the relative risk (RR) of mortality and on the rate of renal recovery between patients treated with either IRRT or CRRT. Furthermore, the use of peritoneal dialysis for the treatment of ARF patients in ICU has not been dismissed yet; so far this is indeed considered to be the technique of choice in some specific clinical situations. The intrinsic urgency of dialysis in ARF patients entails the use of temporary central venous catheters. The internal right jugular vein is usually preferred for these catheters because of the easier insertion and the lower risk of stenosis and thrombosis. The anticoagulant procedure should be chosen on the basis of patient characteristics, treatment typology and the likelihood of effectively monitoring its action. The choice of buffers in the dialysate, mostly lactate or bicarbonate, should depend on patient characteristics; so far, however, controlled but not randomized studies do not show any significant difference in the correction of metabolic acidosis between lactate and bicarbonate.
入住重症监护病房(ICU)的患者发生急性肾衰竭(ARF),大多是由缺血性或中毒性损伤所致。近年来,由于心脏和血管手术干预措施增多以及复苏技术普遍提高,使得ICU患者有更好的预后,ARF的发病率也有所上升。在危重症患者中,文献报道的ARF发病率在1%至25%之间。在患有ARF的ICU患者中,死亡率在40%至65%之间,远高于未发生该并发症的患者。更高的死亡率、更长的住院时间以及更高的治疗费用,要求我们对ARF进行早期诊断和治疗。由于缺乏对照和随机证据,推荐的在重症ARF患者中开始肾脏替代治疗(RRT)的标准可能与终末期肾病(ESRD)治疗的标准重叠。此外,尚无随机对照试验证实早期开始RRT对死亡率的实际疗效。对于稳定的ESRD患者,已确定透析剂量与ARF患者的死亡率和发病率之间存在直接关系。对于ARF患者以及ESRD患者,应确保每周三次的最低Kt/V为1.2,不过对于重症ARF患者,更高的剂量可能会取得更好的效果。在这些患者中,选择间歇性肾脏替代治疗(IRRT)还是连续性肾脏替代治疗(CRRT)仍然是一个有争议的问题。尽管大多数研究报告接受CRRT治疗的患者预后更好,但最近的一项荟萃分析未能证明接受IRRT或CRRT治疗的患者在死亡率相对风险(RR)和肾脏恢复率方面存在任何差异。此外,在ICU中使用腹膜透析治疗ARF患者的做法尚未被摒弃;到目前为止,在某些特定临床情况下,这确实被认为是首选技术。ARF患者透析的内在紧迫性需要使用临时中心静脉导管。这些导管通常首选右侧颈内静脉,因为其插入更容易,且发生狭窄和血栓形成的风险较低。抗凝程序应根据患者特征、治疗类型以及有效监测其作用的可能性来选择。透析液中缓冲剂的选择,主要是乳酸盐或碳酸氢盐,应取决于患者特征;然而,到目前为止,对照但非随机的研究并未显示乳酸盐和碳酸氢盐在纠正代谢性酸中毒方面有任何显著差异。